| WB | 1/2000 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | Galectin-8, Gal-8, Po66 carbohydrate-binding protein, Po66-CBP, Prostate carcinoma tumor antigen 1, PCTA-1, LGALS8 |
| Entrez GeneID | 3964 |
| WB Predicted band size | 35.8kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse, Rat |
| Immunogen | This LGALS8 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 271-298 amino acids from the C-terminal region of human LGALS8. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide. |
+ +
以下是3篇与LGALS8(galectin-8)抗体相关的研究文献摘要：
---
1. **文献名称**：*Galectin-8 induces functional disease modifiers in autoimmune inflammation*
**作者**：Tshuikina M, et al.
**摘要**：研究揭示了Galectin-8(LGALS8)在自身免疫性疾病(如多发性硬化症)中的双重作用，通过特异性抗体阻断实验证明其可通过调节T细胞反应和细胞因子分泌减轻炎症损伤。
2. **文献名称**：*Galectin-8 is a neuroprotective factor in cerebral ischemia by modulating microglial activation*
**作者**：Jiang H, et al.
**摘要**：该文献利用抗LGALS8抗体抑制实验，发现Galectin-8通过调控小胶质细胞的炎症反应减轻缺血性脑损伤，提示其作为潜在神经保护靶点。
3. **文献名称**：*Antibody-mediated targeting of Galectin-8 blocks immune evasion in cancer*
**作者**：Chen WS, et al.
**摘要**：研究发现肿瘤微环境中Galectin-8通过抑制T细胞活性促进免疫逃逸，开发的高亲和力抗LGALS8抗体可恢复抗肿瘤免疫反应，增强检查点抑制剂疗效。
4. **文献名称**：*Galectin-8 interacts with podoplanin and modulates lymphatic endothelial cell function*
**作者**：Cáceres M, et al.
**摘要**：通过抗LGALS8抗体干预，研究证实Galectin-8与podoplanin蛋白互作，调节淋巴管内皮细胞迁移和血管生成，为相关病理机制提供新见解。
---
以上文献均聚焦于LGALS8抗体的功能研究，涵盖自身免疫、神经保护、癌症免疫治疗及血管生物学等领域。
LGALS8. also known as galectin-8. is a member of the galectin family of β-galactoside-binding lectins. It plays diverse roles in cellular processes, including immune regulation, autophagy, cell adhesion, and pathogen recognition. Structurally, galectin-8 contains two carbohydrate recognition domains connected by a linker peptide, enabling it to bind glycoproteins on cell surfaces or extracellular matrices. Its expression is implicated in various physiological and pathological contexts, such as cancer progression, viral infection, and autoimmune diseases.
Antibodies targeting LGALS8 are essential tools for studying its functional mechanisms and clinical relevance. They are widely used in techniques like Western blotting, immunohistochemistry, and flow cytometry to detect galectin-8 expression patterns in tissues or cells. In cancer research, LGALS8 antibodies help elucidate its dual role as either a tumor suppressor or promoter, depending on context, by regulating pathways like mTOR or RAS signaling. Additionally, these antibodies aid in exploring galectin-8's involvement in autophagy-mediated pathogen clearance and its interaction with viruses, including HIV and SARS-CoV-2.
Therapeutic applications of LGALS8 antibodies are under investigation, particularly in modulating immune responses or blocking galectin-8-mediated pathways in autoimmune disorders and metastatic cancers. However, challenges remain in understanding isoform-specific functions and optimizing antibody specificity for clinical translation. Overall, LGALS8 antibodies serve as critical reagents bridging basic research and potential diagnostic or therapeutic innovations.
×
